Medical News
Predictors of Mortality Rate Among Adult HIV-positive Patien...
AIDS Res. Ther.
The incidence of death was high. Being male, viral load, those with advanced STAGE (III & IV), TB co-infected,...
10 May 2021
Integrase Inhibitors Versus Efavirenz Combination Antiretrov...
AIDS Res. Ther.
This meta-analysis demonstrates similar efficacy and safety of INIs-based ART compared with EFV-based ART. This...
05 May 2021
Virologic Outcomes of Switching to Dolutegravir Functional M...
AIDS Res.Ther.
In this real-world cohort, the majority of whom had virus with the M184V/I and ≥ 1 additional NA mutation,...
04 May 2021
A Randomized Controlled Trial Evaluating Combination Detecti...
JIAS
Combining three distinct HIV testing and referral strategies increased the detection of previously undiagnosed HIV...
03 May 2021
eCMEs
Key Trials
Benefits of Inhaled Budesonide in Early COVID-19 Infection: STOIC Study
This infographic summarises the key points of the STOIC study and outlines the benefits of administering inhaled budesonide in early COVID-19...
48-week Efficacy and Safety of Switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide in Virologically Suppressed People Living with HIV aged > 65 years
The presents study evaluated efficacy and safety of switching older people with HIV to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)....
Efficacy of Reduced Doses of both TDF and EFV for the Treatment of HIV-1 Infection
This study is the first randomized, controlled trial in an antiretroviral-naive population that evaluated the efficacy of reduced doses of both...
144-week Efficacy and Safety of Fixed-dose Combination Bictegravir, Emtricitabine, and Tenofovir alafenamide versus Dolutegravir-containing Regimens for Initial Treatment of HIV-1 Infection
This is a randomised, double-blind, multicentre, phase 3 trial evaluating 144-week efficacy and safety of fixed-dose combination bictegravir,...
Our Publications
Antiretroviral-based Prevention Strategies in HIV
Today, antiretroviral therapy (ART) is not only known to keep HIV-infected patients alive but is also being harnessed as a strategy to prevent...
Antiretroviral Therapy – Current Recommendations
Advances in the treatment of HIV infection has resulted in a dramatic shift, from a deadly infectious disease to a chronic manageable condition....
Datasheet: Lopinavir and Ritonavir (40mg/10mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This datasheet contains the entire...
Fast Facts: Lopinavir and Ritonavir (40 mg/10 mg) Oral Pellets
Lopinavir and Ritonavir (40 mg / 10 mg) Oral Pellets is a Novel oral pellet formulation for paediatric use. This booklet contains information about...
Patient Education
Live Healthier, Live Longer
This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment....
Living with Hope
This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects. ...
Slide Library
HIV - HCV Coinfection
This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use
PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...
HIV- Post-exposure Prophylaxis (PEP)
Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...
Isoniazid Preventive Therapy in HIV Infection
HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....
Poll
Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
Efavirenz 400
Dolutegravir
Total votes: 6